Androgen deprivation therapy may increase risk of cardiac-related death in patients with cardiac issues

Share this content:

the ONA take:

According to a new study published in the journal BJU International, researchers from Harvard Medical School and Brigham and Women's Hospital Cancer Center in Boston, Massachusetts, have found that men who were treated with androgen deprivation therapy for prostate cancer and have a past medical history of congestive heart failure or prior myocardial infarction have a three times increased risk of death from cardiac problems compared with those with no history of heart problems.

Previous studies have identified cardiac adverse effects from androgen deprivation therapy, so the team from Boston sought to investigate the association further. The researchers identified 5,077 patients with prostate cancer who received treatment between 1997 and 2006.

Patients were followed for a median of 4.8 years. Of the 30% that received androgen deprivation therapy, there was no association between androgen deprivation therapy and cardiac-related death among men with no history of cardiac issues. Men with a history of cardiac problems were found to have a 3.3-times increased risk of cardiac-related death compared with patients without cardiac issues.

The researchers explain that this study is limited by its retrospective design, and that future studies should follow patients for a longer period of time.

Androgen deprivation therapy may increase risk of cardiac-related death in patients with cardiac iss
Men who were treated with ADT for prostate cancer have a three times increased risk of cardiac problems.

One of the main treatments for prostate cancer, androgen deprivation therapy (ADT) reduced male hormone levels in an effort to prevent them from stimulating cancer cells. However, previous studies have found some adverse effects to be associated with ADT, including increased risk of diabetes, coronary heart disease, heart attacks and sudden cardiac death.

To further investigate this link, a group of researchers from Brigham and Women's Cancer Center and Harvard Medical School - both in Boston, MA - analyzed data from 5,077 prostate cancer patients who were treated between 1997 and 2006. About 30% of the participants had been treated with ADT.

READ FULL ARTICLE From Medical News Today
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs